Top health stocks under US$50

The healthcare sector is comprised of companies that develop and sell medical products and services. Hospital chains, pharmaceutical and biotechnology companies and health insurance firms fall in this category. Healthcare companies have witnessed strong growth during the pandemic.

Here we explore top healthcare stocks in the market.

Pfizer, Inc. (NYSE: PFE)

Pfizer, Inc, a major pharmaceutical biotechnology company, is developing Covid-19 vaccines.

PFE’s stock traded at US$39.79 at 7.52 am ET on July 13, up by 0.08 percent from the closing price of Monday. Its stock price increased by 8.09 percent YTD and 15.61 percent YoY. Its market cap is US$222.5 billion.

Also read: 8 healthcare stocks to explore in July

Source: Pixabay.

The P/E ratio and the forward P/E 1-year of PFE are 20.29 and 10.69, respectively. Its earnings per share were US$1.96, and its annual dividend was US$1.56. The dividend yield is 3.94 percent and the beta is 0.74. PFE’s 52-week highest stock price was US$43.08, and the lowest was US$33.36. Its share volume is 24,512,950.

The company’s total revenue was US$14.5 billion in Q1, 2021, up from US$10 billion YoY. It reported a net income of US$4.8 billion or US$0.86 per share in Q1, 2021, compared to US$3.3 billion or US$0.60 per share in Q1, 2020.

Also read: Aerpio Pharmaceuticals (ARPO): Trending healthcare penny stock

Clene Inc (Nasdaq: CLNN)

Clene Inc, a biotechnology and pharmaceutical company, develops therapeutics for neurodegenerative ailments. CLNN’s stock traded at US$14.03 at 8.07 am ET on July 13, up by 7.59 percent over the closing price of Monday. Its stock price increased by 85.86 percent YTD and 29.20 percent YoY. Its market cap is US$789 million.

The forward P/E 1-year of PFE is -27.17, and the beta is -0.13. CLNN’s 52-week highest stock price was US$16.50, and the lowest was US$6.23. Its share volume is 2,570,994. The company had US$48 million in cash in Q1, 2021, which ended on March 31.

Source: Pixabay.

PLx Pharma Inc (Nasdaq: PLXP)

PLx Pharma Inc. produces and sells anti-inflammatory drugs. PLXP’s stock traded at US$15.10 at 8.22 am ET on July 13, up 21.48 percent from the closing price of yesterday. Its stock price rose by 162.60 percent YTD and 424.30 percent YoY. Its market cap is US$285 million.

The forward P/E 1-year of PFE is -15.60. Its earnings per share were US$2.66, and its beta was 5.09. PLXP’s 52-week highest stock price was US$16.19, and the lowest was US$2.72. Its share volume is 562,755.

PLXP reported a net loss of US$11.9 million or US$0.73 per share in Q1, 2021, cash and cash equivalents of US$84.4 million.

Also read: Intellia (NTLA) stock rally can chart a new path for CRISPR stocks

Genmab A/S (Nasdaq: GMAB)

Genmab A/S, a biotech company, develops antibody therapeutics for cancer treatment.

GMAB’s stock traded at US$43.34 at 8.46 am ET on July 13, down by 1.12 percent over the closing price of yesterday. Its stock price increased by 6.32 percent YTD and 24.75 percent YoY. Its market cap is US$28.6 billion.

The P/E ratio and the forward P/E 1-year of PFE are 33.72 and 76.89, respectively. The company recorded earnings per share of US$1.30 and beta 0.57. GMAB’s 52-week highest stock price was US$44.92, and the lowest was US$30.10. Its share volume is 259,026.

Net sales of GMAB were US$1.3 billion in Q1, 2021, which ended on March 31, and that was US$937 million in Q1, 2020.

Also read: Where is Doximity Inc. (NYSE: DOCS) stock headed?

Royalty Pharma plc (Nasdaq: RPRX)

Royalty Pharma plc, a biotechnology company, provides funding to life sciences research directly or indirectly.

PFE’s stock traded at US$41.71 at premarket on July 13, down by 0.14 percent over the closing price of yesterday. Its stock prices decreased by 10.93 percent YTD and 5.33 percent YoY. The market capitalization of the company is US$25.3 billion.

The P/E ratio and the forward P/E 1-year of PFE are 26.07 and 15.22, respectively. The company recorded earnings per share of US$1.60. Its annual dividend was US$0.68, and its dividend yield was 1.63 percent. The beta is 0.99. RPRX’s 52-week highest stock price was US$53.23, and the lowest was US$34.80. Its share volume is 3,630,347.

Net cash generated from operating activities in Q1, 2021, ended on March 31, was US$526 million. It was US$471 million in Q1, 2020. Total income and other revenues were US$573 million in Q1, 2021, and US$501 million in Q1, 2020.

Also read: Three healthcare penny stocks to explore

Neogen Corporation (Nasdaq: NEOG)

Neogen Corporation provides solutions and services for the food processing and the agriculture industry. It also serves the field of life sciences. NEOG’s stock traded at US$46.25 at 9.25 am ET on July 13, up by 0.43 percent over the closing price of Monday. Its stock price increased by 17.96 percent YTD and 19.91 percent YoY. Its market cap is US$13.9 billion.

The P/E ratio and the forward P/E 1-year of PFE are 79.4 and 79.40, respectively. The company recorded earnings per share of US$0.58, and the beta is 0.49. NEOG’s 52-week highest stock price was US$48.85, and the lowest was US$33.11. Its share volume is 305,508.

The company reported revenue of US$116 million in Q3, 2021, ended on February 28, up 17 percent YoY. The net income was US$13.3 million or US$0.25 per share in Q3, 2021. It was US$12.2 million or US$0.23 per share in Q3, 2020. 

Also read: Why is Cerevel Therapeutics stock (CERE) trending today?

Grifols, S.A. (Nasdaq: GRFS)

Grifols, S.A., a pharmaceutical company, produces blood plasma-based products.

GRFS’s stock traded at US$15.93 at 9.38 am ET on July 13, down by 3.34 percent over the closing price of yesterday. Its stock prices decreased by 15.93 percent YTD. The market capitalization of the company is US$11.1 billion.

The P/E ratio and the forward P/E 1-year of PFE are 17.18 and 13.09, respectively. The company recorded earnings per share of US$0.96. Its annual dividend was US$0.72, and the current yield is 4.32 percent. Beta is 0.59.

Please note: The above constitutes a preliminary view, and any interest in stocks/cryptocurrencies should be evaluated further from an investment point of view.